The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Managing sickle cell disease in daily practice: when are different agents indicated?
Abdullah Kutlar, MD, Augusta University, Augusta, GA, talks on the practical aspects of integrating novel agents into clinical practice for the management of sickle cell disease (SCD). Three new agents have been approved in the last four years, transforming the SCD treatment paradigm after nearly 20 years with no new approvals for adult patients. Prof. Kutlar explains how these agents are used in daily practice and why different options are indicated in different scenarios. Prof. Kutlar goes on to share his experience managing patients receiving a combination of agents and how this may represent an important future strategy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
